Skip to main content

Table 1 Clinical characteristics of analyzed EOC patients

From: CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients

Criteria Sporadic EOC Mutated EOC
n % n %
FIGO     
I 13 6.9 3 20.0
II 6 3.2 0 0.0
III/IV 165 87.8 12 80.0
Missing 4 2.1 0 0.0
Grading     
G1 6 3.2 3 20.0
G2 29 15.4 2 13.3
G3 147 78.2 10 66.7
Missing 6 3.2 0 0.0
pT     
T1a 6 3.2 1 6.7
T1b 1 0.5 0 0.0
T1c 7 3.7 2 13.3
T2a 8 4.3 0 0.0
T2c 7 3.7 0 0.0
T3a 8 4.3 0 0.0
T3b 20 10.6 2 13.3
T3c 129 68.6 10 66.7
Missing 2 1.1 0 0.0
pN     
N0 60 31.9 5 33.3
N1 114 60.6 7 46.7
Nx 14 7.4 3 20.0
pM     
M0 137 72.9 12 80.0
M1 35 18.6 3 20.0
Mx 16 8.5 0 0.0
Histology     
Serous 156 83.0 13 86.7
Endometrioid 15 8.0 0 0.0
Mucinous 3 1.6 2 13.3
Other 14 7.4 0 0.0
Resection     
R0 141 75.0 12 80.0
R1/R2 42 22.3 3 20.0
Missing 5 2.7 0 0.0
Chemotherapy    
Carbo/Pac 150 79.8 13 86.7
Carbo 8 4.3 0 0.0
Carbo/Pac + x 11 5.9 0 0.0
Carbo + x 8 4.3 1 6.7
Other 3 1.6 0 0.0
None 7 3.7 1 6.7
Missing 1 0.5 0 0.0
Bevacizumab    
Yes 29 15.4 5 33.3
No 157 83.5 10 66.7
Missing 2 1.1 0 0.0
Complete 188 100.0 15 100.0